Angina (Angina Pectoris) - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Angina (Angina Pectoris) - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Angina (Angina Pectoris) - Pipeline Review, H1 2015', provides an overview of the Angina (Angina Pectoris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Angina (Angina Pectoris) Overview 9
Therapeutics Development 10
Pipeline Products for Angina (Angina Pectoris) - Overview 10
Pipeline Products for Angina (Angina Pectoris) - Comparative Analysis 11
Angina (Angina Pectoris) - Therapeutics under Development by Companies 12
Angina (Angina Pectoris) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Angina (Angina Pectoris) - Products under Development by Companies 17
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 19
Bayer AG 19
Cardiolynx AG 20
CJ CheilJedang Corp. 21
Gilead Sciences, Inc. 22
Hemostemix Ltd 23
Jiangsu Hengrui Medicine Co., Ltd. 24
Juventas Therapeutics, Inc. 25
Kuhnil Pharmaceutical Co., Ltd. 26
Lacer, S.A. 27
Lee's Pharmaceutical Holdings Limited 28
LegoChem Biosciences, Inc 29
Milestone Pharmaceuticals, Inc. 30
Taxus Cardium Pharmaceuticals Group Inc. 31
ViroMed Co., Ltd. 32
Angina (Angina Pectoris) - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ACP-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
aladorian sodium - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
alferminogene tadenovec - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BAY-606583 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CJ-30059 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CLC-1201 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CLC-1280 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GS-6615 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ivabradine hydrochloride SR - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
JVS-100 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KI-1007 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LA-419 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LA-8045 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MSP-2017 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule to Activate Soluble Guanylate Cyclase for Angina Pectoris - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VM-202 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZK-001 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Angina (Angina Pectoris) - Recent Pipeline Updates 68
Angina (Angina Pectoris) - Dormant Projects 76
Angina (Angina Pectoris) - Discontinued Products 79
Angina (Angina Pectoris) - Product Development Milestones 80
Featured News & Press Releases 80
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 80
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 82
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 83
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 84
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 86
Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280 87
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 88
Apr 18, 2011: Lee's Pharma Completes Phase I Study Of Anti-Platelet Drug Declotana 89
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 89
Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H1 2015 10
Number of Products under Development for Angina (Angina Pectoris) - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Angina (Angina Pectoris) - Pipeline by Bayer AG, H1 2015 19
Angina (Angina Pectoris) - Pipeline by Cardiolynx AG, H1 2015 20
Angina (Angina Pectoris) - Pipeline by CJ CheilJedang Corp., H1 2015 21
Angina (Angina Pectoris) - Pipeline by Gilead Sciences, Inc., H1 2015 22
Angina (Angina Pectoris) - Pipeline by Hemostemix Ltd, H1 2015 23
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 24
Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H1 2015 25
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 26
Angina (Angina Pectoris) - Pipeline by Lacer, S.A., H1 2015 27
Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 28
Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H1 2015 29
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H1 2015 30
Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H1 2015 31
Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 35
Number of Products by Stage and Mechanism of Action, H1 2015 37
Number of Products by Stage and Route of Administration, H1 2015 39
Number of Products by Stage and Molecule Type, H1 2015 41
Angina (Angina Pectoris) Therapeutics - Recent Pipeline Updates, H1 2015 68
Angina (Angina Pectoris) - Dormant Projects, H1 2015 76
Angina (Angina Pectoris) - Dormant Projects (Contd..1), H1 2015 77
Angina (Angina Pectoris) - Dormant Projects (Contd..2), H1 2015 78
Angina (Angina Pectoris) - Discontinued Products, H1 2015 79